News
- Author:
- Mary Jo M. Dales
Publish date: March 24, 2014
Major finding: Metastasis-free survival was 31% and overall survival was 49% at 5 years in the 64 patients who had negative sentinel node lymph bi...
News
- Author:
- Mary Jo M. Dales
Publish date: March 23, 2014
Major finding: Two cases of surgically operable, metastatic Merkel cell tumors, one metastatic to the kidney and the other to the pancreas, were d...
News
- Author:
- Mary Jo M. Dales
Publish date: December 11, 2013
News
- Author:
- Mary Jo M. Dales
Publish date: August 27, 2013
Major finding: In patients randomly assigned to 2 years of ibandronate or observation, there was no difference in disease-free survival (HR, 0.945...
News
- Author:
- Mary Jo M. Dales
Publish date: August 27, 2013
Major finding: The probabilities of chemotherapy-induced amenorrhea were 7.2% for women diagnosed at or before age 30 years, 33% for women diagnos...
News
- Author:
- Mary Jo M. Dales
Publish date: August 27, 2013
Major finding: Based on BRCA1 status alone, the 10-year survival rate for mutation carriers was 80.9% (95% CI, 75.4%-86.4%); for noncarriers, it w...
News
- Author:
- Mary Jo M. Dales
Publish date: July 12, 2013
Major finding: In conservatively managed prostate cancer patients, the cell cycle progression score in tissue samples was the dominant variable fo...
News
- Author:
- Mary Jo M. Dales
Publish date: June 13, 2013
News
- Author:
- Mary Jo M. Dales
Publish date: June 6, 2013
Major finding: Of 56 African American women with gene mutations, 26 were positive for BRCA1, 20 were positive for BRCA2, and 10 were positive for ...
News
- Author:
- Mary Jo M. Dales
Publish date: June 3, 2013
Major finding: Tumors regressed in 11% (RECIST response, 0%) of 46 evaluable patients in the temozolomide arm and in 50% (RECIST response, 15%) of...
News
- Author:
- Mary Jo M. Dales
Publish date: May 16, 2013
Major finding: Single agent idelalisib elicited 2 complete responses and 28 partial responses in 54 heavily pretreated patients with chronic lymph...
News
- Author:
- Mary Jo M. Dales
Publish date: May 16, 2013
Major finding: Tumor reductions of at least 80% were seen at 12 weeks in 11 of 37 (30%) of patients.Data source: A phase-I, dose-ranging study of ...
News
- Author:
- Mary Jo M. Dales
Publish date: May 15, 2013
Major finding: MPDL3280A, an engineered PD-L1 targeted antibody, shrank tumors by at least 50% in 29 of 140 patients, for an overall response rate...
News
- Author:
- Mary Jo M. Dales
Publish date: May 2, 2013
News
- Author:
- Mary Jo M. Dales
Publish date: March 21, 2013
